Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Shares Outstanding (Diluted Average): 2022-2025

Historic Shares Outstanding (Diluted Average) for Corvus Pharmaceuticals (CRVS) over the last 2 years, with Mar 2025 value amounting to $75.2 million.

  • Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) rose 53.25% to $75.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $75.2 million, marking a year-over-year increase of 53.25%. This contributed to the annual value of $61.0 million for FY2024, which is 26.99% up from last year.
  • Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $75.2 million in Q1 2025, which was up 23.23% from $61.0 million recorded in Q4 2024.
  • In the past 5 years, Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) ranged from a high of $75.2 million in Q1 2025 and a low of $46.6 million during Q1 2022.
  • For the 3-year period, Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $53.7 million, with its median value being $49.0 million (2023).
  • Data for Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 53.25% (in 2025) over the last 5 years.
  • Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $46.6 million in 2022, then rose by 3.16% to $48.0 million in 2023, then increased by 26.99% to $61.0 million in 2024, then skyrocketed by 53.25% to $75.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $75.2 million in Q1 2025, compared to $61.0 million in Q4 2024 and $49.0 million in Q1 2024.